<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1601256676
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2008
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LECITAL 20MG F.C. CAPLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CITALOPRAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        34.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jordan Sweden Medical and Sterilization Co." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jordan Sweden Medical and Sterilization Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 679]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL-DAWAA MEDICAL SERVICES CO. LTD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jordan Sweden Medical and Sterilization Co.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AB04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>How does Lecital work?<br />Lecital is a Selective Serotonin Reuptake Inhibitor (SSRI) and belongs to a group of medicines known as antidepressants. These medicines help to correct certain chemical imbalances in the brain that are causing the symptoms of your illness.<br />What is Lecital used for?<br />Lecital contains citalopram and is used for the treatment of depression and, when you feel better, to help prevent these symptoms recurring. Lecital is also used for long-term treatment to prevent the occurrence of new episodes of depression if you have recurrent depression.<br />Lecital is also beneficial in relieving symptoms if you tend to suffer from panic disorder with or without agoraphobia.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>A.Do not take Lecital if:</p><p>&bull; If you are allergic to citalopram or to any of the other ingredients of this medicine (listed in section 6). Consult your doctor if you think you might be.</p><p>&bull; At the same time as taking medication known as monoamine oxidase inhibitors (MAOIs). MAOIs include medicines such as phenelzine, iproniazid, isocarboxazid, nialamide, tranylcypromine and moclobemide (used for the treatment of depression), selegiline (used in the treatment of Parkinson&rsquo;s disease) and linezolid (an antibiotic). Even if you have finished taking one of the following MAOIs: phenelzine, iproniazid, isocarboxazid, nialamide or tranylcypromine you will need to wait 2 weeks before you start taking your Lecital Caplets. One day must elapse after you have finished taking moclobemide. After stopping Lecital you must allow 1 week before taking any MAOI</p><p>&bull; If you are born with or have had an episode of abnormal heart rhythm (seen at ECG; an examination to evaluate how the heart is functioning).</p><p>&bull; If you take medicines for heart rhythm problems or that may affect the heart&rsquo;s rhythm (see Other medicines and Lecital below).</p><p>B.Take special care with Lecital:</p><p>&nbsp;</p><p>Suicidality and Antidepressant Drugs:</p><p>&bull; Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders.</p><p>&bull; Anyone considering the use of Citalopram or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need.</p><p>&bull; Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide.</p><p>&bull; Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior.</p><p>&bull; Families and caregivers should be advised of the need for close observation and communication with the prescriber.</p><p>&bull; Citalopram is not approved for use in pediatric patients.</p><p>Please tell your doctor if you have any medical problems, especially if you have:</p><p>&bull; Liver disease.</p><p>&bull; Kidney disease.</p><p>&bull; Diabetes (you may need an adjustment of your antidiabetic therapy).</p><p>&bull; Epilepsy or a history of seizures or fits.</p><p>&bull; A bleeding disorder or have ever suffered from bleeding in the stomach or intestine.</p><p>&bull; Mania or panic disorder.</p><p>&bull; Low blood levels of sodium.</p><p>&bull; ECT (electroconvulsive therapy).</p><p>&bull; Problems with your eyes, such as certain kinds of glaucoma.</p><p>&bull; Suffered or suffer from heart problems or have recently had a heart attack.</p><p>&bull; A low resting heart-rate and/or you know that you may have salt depletion as a result of prolonged severe diarrhoea and vomiting (being sick) or usage of diuretics (water Tablets).</p><p>&bull; Experienced a fast or irregular heartbeat, fainting, collapse or dizziness on standing up which may indicate abnormal functioning of the heart rate.</p><p>Please consult your doctor, even if these statements were applicable to you at any time in the past.</p><p>Please note:</p><p>Some patients with manic-depressive illness may enter into a manic phase. This is characterized by unusual and rapidly changing ideas, inappropriate happiness and excessive physical activity. If you experience this, contact your doctor.</p><p>Symptoms such as restlessness or difficulty in sitting or standing still can also occur during the first weeks of the treatment. Tell your doctor immediately if you experience these symptoms.</p><p>Special information relating to your disease:</p><p>As with other medicines used to treat depression or related diseases, the improvement is not achieved immediately. After the start of Lecital treatment it may take several weeks before you experience any improvement. In the beginning of the treatment certain patients may experience increased anxiety, which will disappear during continued treatment. Therefore, it is very important that you follow exactly your doctor&rsquo;s orders and do not stop the treatment or change the dose without consulting your doctor.</p><p>Thoughts of suicide and worsening of your depression or anxiety disorder:</p><p>&bull; If you are depressed and/or have anxiety disorders you can sometimes have thoughts of harming or killing yourself. These may be increased when first starting antidepressants, since these medicines all take time to work, usually about two weeks but sometimes longer.</p><p>You may be more likely to think like this:</p><p>&bull; If you have previously had thoughts about killing or harming yourself.</p><p>&bull; If you are a young adult. Information from clinical trials has shown an increased risk of suicidal behaviour in adults aged less than 25 years with psychiatric conditions who were treated with an antidepressant.</p><p>If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away.</p><p>You may find it helpful to tell a relative or close friend that you are depressed or have an anxiety disorder, and ask them to read this leaflet. You might ask them to tell you if they think your depression or anxiety is getting worse, or if they are worried about changes in your behaviour.</p><p>Use in children and adolescents under 18 years of age:</p><p>Lecital should normally not be used for children and adolescents under 18 years. Also, you should know that patients under 18 have an increased risk of side effects such as suicide attempt, suicidal thoughts and hostility (predominantly aggression, oppositional behavior and anger) when they take this class of medicines. Despite this, your doctor may prescribe citalopram for patients under 18 because he/she decides that this is in their best interests. If your doctor has prescribed Lecital for a patient under 18 and you want to discuss this, please go back to your doctor. You should inform your doctor if any of the symptoms listed above develop or worsen when patients under 18 are taking Lecital. Also, the long-term safety effects concerning growth, maturation and cognitive and behavioral development of Lecital in this age group have not yet been demonstrated.</p><p>C.Taking other medicines:</p><p>Medicines may affect the action of other medicines and this can sometimes cause serious adverse reactions. Please tell your doctor or pharmacist if you are taking, have taken or might take any other medicines. This includes other medicines for depression (see Do not take Lecital).</p><p>&bull; The herbal remedy St John&rsquo;s wort (Hypericum perforatum). This should not be taken at the same time as Lecital.</p><p>&bull; Monoamine oxidase inhibitors (MAOIs). These should not be taken at the same time as Lecital (see Do not take Lecital).</p><p>&bull; Tell your doctor if you are taking any of the following medicines:</p><p>&bull; Linezolid (an antibiotic).</p><p>&bull; Sumatriptan (used to treat migraine) or tramadol (a pain killer). If you feel unwell when using these medicines with Lecital you should see your doctor.</p><p>&bull; Lithium (used to prevent and treat mania) and tryptophan (an antidepressant).</p><p>&bull; Pimozide (a neuroleptic). This should not be taken at the same time as Lecital.</p><p>&bull; Imipramine and desipramine (used to treat depression).</p><p>&bull; Medicines containing selegiline (used to treat Parkinson&rsquo;s disease).</p><p>&bull; Cimetidine (used to treat stomach ulcers).</p><p>&bull; Mefloquine&nbsp;(used to treat malaria).</p><p>&bull; Bupropion (used to treat depression).</p><p>&bull; Medicines known to affect the blood platelets (e.g. anticoagulant drugs used to treat or prevent blood clots; aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and diclofenac used as painkillers and some antipsychotic drugs and tricyclic antidepressants).</p><p>&bull; Metoprolol, a beta blocker used to treat migraine, some heart conditions and high blood pressure. The effects of either drug could be increased, decreased or altered.</p><p>&bull; Neuroleptics (used in the treatment of schizophrenia).</p><p>Do not take Lecital if you take medicines for heart rhythm problems or medicines that may affect the heart&rsquo;s rhythm, e.g. such as Class IA and III antiarrhythmics, antipsychotics (e.g. phenothiazine derivatives, pimozide, haloperidol), tricyclic antidepressants, certain antimicrobial agents (e.g. sparfloxacin, moxifloxacin, erythromycin IV, pentamidine, anti-malarial treatment particularly halofantrine), certain antihistamines (astemizole, mizolastine). If you have any further questions about this you should speak to your doctor.</p><p>D.Taking Lecital with food, drink and alcohol:</p><p>Lecital can be taken with or without food (see section 3 &ldquo;How to take Lecital&rdquo;).</p><p>As with all antidepressants, it is sensible to avoid drinking alcohol whilst receiving treatment although Lecital has not been shown to increase the effects of alcohol.</p><p>E.Pregnancy, breast-feeding and fertility:</p><p>Pregnancy:</p><p>Ask your doctor or pharmacist for advice before taking any medicine. If you are pregnant, think you might be pregnant, or are trying to become pregnant, tell<br />your doctor. Do not take Lecital if you are pregnant unless you and your doctor have discussed the risks and benefits involved.<br />Make sure your midwife and/or doctor know you are on Lecital. When taken during pregnancy, particularly in the last 3 months of pregnancy, medicines like<br />Lecital may increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe<br />faster and appear bluish. These symptoms usually begin during the first 24 hours after the baby is born. If this happens to your baby you should contact<br />your midwife and/or doctor immediately. Also, if you take Lecital during the last 3 months of your pregnancy and until the date of birth you should be aware that<br />the following effects may be seen in your newborn: fits, being too hot or cold, feeding difficulties, vomiting, low blood sugar, stiff or floppy muscles, overactive reflexes, tremor, jitteriness, irritability, lethargy, constant crying, sleepiness or sleeping difficulties. If your newborn baby gets any of these symptoms please contact your midwife and/or doctor immediately.</p><p>Breast-feeding:</p><p>Ask your doctor or pharmacist for advice before taking any medicine. If you are breast-feeding, ask your doctor for advice. You should not breast-feed your baby when taking Lecital because small amounts of the medicine can pass into the breast milk.</p><p>Fertility:</p><p>Citalopram has been shown to reduce the quality of sperm in animal studies. Theoretically, this could affect fertility, but impact on human fertility has not been observed as yet.</p><p>F.Driving and using machines:</p><p>Lecital does not usually affect the ability to carry out normal daily activities. However, if you feel dizzy or sleepy when you start to take this medicine, you should be careful when driving, operating machinery or performing jobs that need you to be alert until these effects wear off.</p><p>G.Important information about some of the ingredients of Lecital:</p><p>This product contains lactose. If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Adults:</p><p>Depression:</p><p>The usual dose is 20 mg per day. This may be increased by your doctor to a maximum of 40 mg per day.</p><p>Panic disorder:</p><p>The starting dose is 10 mg per day for the first week before increasing the dose to 20-30 mg per day. The dose may be increased by your doctor to a maximum of 40 mg per day.</p><p>Elderly patients (above 65 years of age):</p><p>The starting dose should be decreased to half of the recommended dose, e.g. 10-20 mg per day. Elderly patients should not usually receive more than 20 mg per day.</p><p>Children and adolescents (less than 18 years of age):</p><p>Lecital should not be given to children or adolescents. For further information, please see section 2, before you take Lecital.</p><p>Patients with special risks:</p><p>Patients with liver complaints should not receive more than 20 mg per day.</p><p>How and when to take Lecital:</p><p>Lecital is taken every day as a single daily dose. Lecital can be taken any time of the day with or without food. Swallow the Caplets with a drink of water. Do not chew them (they have a bitter taste).</p><p>Duration of treatment:</p><p>Like other medicines for depression and panic disorder these Caplets may take a few weeks before you feel any improvement. Continue to take Lecital even if it takes some time before you feel any improvement in your condition. The duration of treatment is individual, usually at least 6 months. Continue to take the Caplets for as long as your doctor recommends. Do not stop taking them even if you begin to feel better, unless you are told to do so by your doctor. The underlying illness may persist for a long time and if you stop your treatment too soon your symptoms may return.</p><p>Patients who have recurrent depression benefit from continued treatment, sometimes for several years, to prevent the occurrence of new depressive episodes.</p><p>Never change the dose of the medicine without talking to your doctor first</p><p>A.If you take more Lecital than you should:</p><p>If you think that you or anyone else may have taken too many Lecital Caplets contact your doctor or nearest hospital emergency department immediately. Do this even if there are no signs of discomfort or poisoning. Take the Lecital box/container with you if you go to a doctor or hospital. Some of the signs of an overdosage could be life-threatening.</p><p>Symptoms of overdosage may include:</p><p>&bull; Irregular heart beat.</p><p>&bull; Seizures.</p><p>&bull; Changes in heart rhythm.</p><p>&bull; Feeling sick (nausea).</p><p>&bull; Vomiting.</p><p>&bull; Sweating.</p><p>&bull; Drowsiness.</p><p>&bull; Unconsciousness.</p><p>&bull; Fast heart beats.</p><p>&bull; Tremor.</p><p>&bull; Changes in blood pressure.</p><p>&bull; Serotonin syndrome (see Section 4).</p><p>&bull; Agitation.</p><p>&bull; Dizziness.</p><p>&bull; Enlarged eye pupils.</p><p>&bull; Bluish skin.</p><p>&bull; Breathing too quickly.</p><p>B.If you forget take Lecital:</p><p>If you forget to take a dose, take the next dose at the usual time. Do not take a double dose.</p><p>C.If you stop taking Lecital:</p><p>Stopping this medicine quickly may cause symptoms such as dizziness, nausea and numbness or tingling in hands or feet, sleep disturbances (vivid dreams, nightmares, inability to sleep), feeling anxious, headaches, feeling or being sick, sweating, feeling restless or agitated, tremor, feeling confused or disorientated, feeling emotional or irritable, diarrhea (loose stools), visual disturbances, fluttering or pounding heartbeat (palpitations). These are usually non-serious and disappear within a few days. When you have completed your course of treatment, the dose of Lecital is usually reduced gradually over a couple of weeks.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines this medicine can cause side effects, although not everybody gets them. Several of the effects listed below can also be symptoms of your illness and may disappear as you start to get better.</p><p>Serious side effects:</p><p>Stop taking Lecital and seek medical advice immediately if you have any of the following symptoms:</p><p>&bull; Difficulty in breathing.</p><p>&bull; Swelling of the face, lips, tongue or throat that causes difficulty in swallowing or breathing.</p><p>&bull; Severe itching of the skin (with raised lumps).</p><p>&bull; Fast, irregular heartbeat, fainting which could be symptoms of a life-threatening condition known as torsades de pointes.</p><p>If you notice any of the following symptoms you should contact your doctor immediately as your dose may need to be reduced or stopped:</p><p>&bull; You start having fits for the first time or fits that you have suffered from in the past become more frequent.</p><p>&bull; Your behavior changes because you feel elated or over excited.</p><p>&bull; You experience high fever, agitation, confusion, trembling or abrupt contractions of muscles. These may be signs of a rare condition called serotonin syndrome.</p><p>&bull; Tiredness, confusion and twitching of your muscles. These may be signs of a low blood level of sodium (hyponatraemia).</p><p>If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away.</p><p>The following side effects are often mild and usually disappear after a few days&rsquo; treatment.</p><p>Very common side effects (may affect more than 1 in 10 people):</p><p>&bull; Sleepiness.</p><p>&bull; Difficulty in sleeping.</p><p>&bull; Headache.</p><p>&bull; Changes in your sleeping pattern.</p><p>&bull; Loss of body strength, weakness.</p><p>&bull; Increased sweating.</p><p>&bull; Dry mouth (a dry mouth increases the risk of tooth decay, so be sure to clean your teeth more often than usual).</p><p>&bull; Feeling sick (nausea).</p><p>Common side effects (may affect up to 1 in 10 people):</p><p>&bull; Lack of appetite.</p><p>&bull; Agitation.</p><p>&bull; Decreased sex drive.</p><p>&bull; Anxiety.</p><p>&bull; Nervousness.</p><p>&bull; Confusion.</p><p>&bull; Abnormal dreams.</p><p>&bull; Reduced emotions, indifference (apathy).</p><p>&bull; Tremor.</p><p>&bull; Tingling or numbness in the hands or feet.</p><p>&bull; Dizziness.</p><p>&bull; Problems concentrating.</p><p>&bull; Migraine.</p><p>&bull; Loss of memory (amnesia).</p><p>&bull; Ringing in the ears (tinnitus).</p><p>&bull; Palpitations.</p><p>&bull; Yawning.</p><p>&bull; Blocked or runny nose (rhinitis).</p><p>&bull; Diarrhoea.</p><p>&bull; Vomiting.</p><p>&bull; Constipation.</p><p>&bull; Stomach pain.</p><p>&bull; Flatulence (wind).</p><p>&bull; Increase in saliva (drooling).</p><p>&bull; Itching.</p><p>&bull; Pain in muscles and joints.</p><p>&bull; For men, problems with ejaculation and erection.</p><p>&bull; For women, failing to reach an orgasm.</p><p>&bull; Tiredness.</p><p>&bull; Prickling of the skin.</p><p>&bull; Loss of weight.</p><p>&nbsp;</p><p>Uncommon (may affect up to 1 in 100 people):</p><p>&bull; Bruising easily.</p><p>&bull; Increased appetite.</p><p>&bull; Aggression.</p><p>&bull; Hallucinations.</p><p>&bull; Mania.</p><p>&bull; Fainting.</p><p>&bull; Large pupils (the dark centre of the eye).</p><p>&bull; Fast heart beat.</p><p>&bull; Slow heart beat.</p><p>&bull; Nettle rash.</p><p>&bull; Loss of hair.</p><p>&bull; Rash.</p><p>&bull; Sensitivity to sunlight.</p><p>&bull; Difficulties urinating.</p><p>&bull; Excessive menstrual bleeding.</p><p>&bull; Swelling of the arms or legs.</p><p>&bull; Increased weight.</p><p>Rare (may affect up to 1 in 1000 people):</p><p>&bull; Increased sex drive</p><p>&bull; Convulsions</p><p>&bull; Involuntary movements</p><p>&bull; Taste disturbances</p><p>&bull; Bleeding</p><p>&bull; Coughing</p><p>&bull; Hepatitis</p><p>&bull; Feeling unwell (malaise)</p><p>Some patient have reported (frequency not known):</p><p>&bull; Thoughts of harming or killing themselves, see also section 2 &ldquo;Before you take Lecital&rdquo;.<br />&bull; An increase in bleeding or bruising caused by a decrease in blood platelets (thrombocytopenia).<br />&bull; Rash (hypersensitivity).<br />&bull; Low potassium levels in the blood (hypokalaemia), which can cause muscle weakness, twitching or abnormal heart rhythms.<br />&bull; Panic attack.<br />&bull; Grinding teeth.<br />&bull; Restlessness.<br />&bull; Unusual muscle movements or stiffness.</p><p>&bull; Involuntary movements of the muscles (akathisia).<br />&bull; Low blood pressure.<br />&bull; Nosebleed.<br />&bull; Bleeding disorders including skin and mucosal bleeding (ecchymosis).<br />&bull; Sudden swelling of skin or mucosa.<br />&bull; In men, painful erections.<br />&bull; Flow of breast milk in men or in women who are not breast-feeding (galactorrhoea)<br />&bull; Irregular menstrual periods.<br />&bull; Abnormal liver function tests.<br />&bull; An increased risk of bone fractures has been observed in patients taking this type of medicines.<br />&bull; Abnormal heart rhythm.</p><p>SSRIs can, very rarely, increase the risk of bleeding, including stomach or intestinal bleeding. Let your doctor know if you vomit blood or develop black or<br />blood stained stools.<br />Also let your doctor know if you continue to have other symptoms associated with your depression. This might include hallucinations, anxiety, mania or confusion.<br />If any of the side effects gets serious or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p>To reports any side effect(s):</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />&bull; Fax: +966-11-205-7662<br />&bull; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />&bull; Toll free phone: 8002490000<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.</p><p>&bull; Do not use Lecital after the expiry date which is stated on the label and carton.</p><p>&bull; This medicinal product does not require any special storage conditions.</p><p>&bull; Do not use any Lecital pack that is damaged or shows signs of tampering.</p><p>&bull; Store below 30oC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lecital 20 contains 20mg of Citalopram (as hydrobromide).</p><p>Lecital 40 contains 40mg of Citalopram (as hydrobromide).</p><p>The other ingredients are: Maize starch/ Povidone/ Croscarmellose/ Lactose monohydrate/ Microcrystalline Cellulose 101 / Microcrystalline Cellulose 102 / Colloidal silicone dioxide/ Magnesium Stearate/Luster Clear (Microcrystalline Cellulose, Carrageenan, Polyethylene Glycol) / Titanium Dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pharmaceutical form: Film Coated Caplet.
Lecital 20 pack size: 30 Film Coated Caplet.
Lecital 40 pack size: 30 Film Coated Caplet.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jordan Sweden Medical and Sterilization Company (Joswe-medical)</p><p>P.O. Box 851831 Amman 11185 Jordan</p><p>E-mail: joswe@go.com.jo</p><p>www.joswe.com</p><p>Tel: +962 6 5859765, +962 6 5728327</p><p>Fax: +962 6 5814526, +962 6 5728326</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 02/2017; Revision number R2
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هي الطريقة التي يعمل بها ليسيتال؟</strong></p><p dir="RTL">يعتبر <strong>ليسيتال</strong> مثبط انتقائي لإعادة امتصاص السيروتونين(SSRI) وينتمي إلى مجموعة من الأدوية تسمى مضادات الإكتئاب. تساعد هذه الأدوية على تصحيح حالات عدم التوازن الكيميائي في الدماغ المسببة لأعراض المرض.</p><p dir="RTL"><strong>ما هي دواعي استخدام ليسيتال؟</strong></p><p dir="RTL">يحتوي<strong> ليسيتال</strong> على سيتالوبرام المستخدم لعلاج الإكتئاب، وبعد الشعور بالتحسن يستخدم لمنع الإصابة بأعراض المرض مرة أخرى. كما يستخدم<strong> ليسيتال</strong> كعلاج طويل الأمد لمنع حدوث حالات جديدة من الإكتئاب إذا كنت تعاني من الإكتئاب المتكرر.</p><p dir="RTL">يعتبر <strong>ليسيتال </strong>مفيد أيضاً لعلاج أعراض الخوف في الأشخاص الذين يعانون من اضطرابات الهلع المصحوبة أو غير المصحوبة برهاب الميادين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ. لا تتناول ليسيتال إذا:</strong></p><p dir="RTL">كنت تعاني من الحساسية ضد سيتالوبرام أو أي من المكونات الأخرى لهذا الدواء (المذكورة تحت البند 6).</p><p dir="RTL">قم باستشارة الطبيب إذا كنت تعتقد بأنك:</p><p dir="RTL">&middot;&nbsp; كنت وفي نفس الوقت تتناول دواء مثل مثبطات أنزيم أحادي الأمين ((MAOIs، وتشمل فينيلزين، إيبرونيازيد، إيزوكربوكسازيد، نيالاميد، ترانيلسيبرومين وموكلوبميد (المستخدم لعلاج الاكتئاب)، سيليجيلين (المستخدم في علاج مرض الشلل الرعاشي) ولينزوليد (مضاد حيوي). حتى لو كنت قد انتهيت من تناول أحد مثبطات أنزيم أحادي الأمين (MAOIs) التالية: فينيلزين، إيبرونيازيد، إيزوكربوكسازيد، نيالاميد أو ترانيلسيبرومين قد تحتاج إلى الإنتظار مدة أسبوعين قبل البدء بتناول أقراص <strong>ليسيتال</strong>. كما يجب الإنتظار لمدة يوم بعد الإنتهاء من تناول موكلوبميد. وبعد التوقف عن تناول<strong> ليسيتال</strong> يجب الإنتظار لمدة أسبوع قبل تناول أي من مثبطات أنزيم أحادي الأمين (MAOIs).&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp; إذا قد عانيت مسبقاً أو منذ الولادة من حالات نبض قلب غير طبيعي (ظهرت على جهاز تخطيط القلب؛ الفحص المستخدم لتقييم كيفية عمل القلب).</p><p dir="RTL">&middot;&nbsp; إذا كنت تتناول أدوية لعلاج مشاكل نبض القلب أو تؤثر على نبض القلب (انظر إلى بند تناول أدوية أخرى مع<strong> ليسيتال</strong>)</p><p dir="RTL"><strong>ب. أخذ الحيطة والحذر عند تناول ليسيتال:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:822px"><tbody><tr><td style="width:819px"><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>أدوية مضادات الإكتئاب والإنتحار:</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;</strong><strong>أظهرت الدراسات قصيرة المدى لإضطرابات الإكتئاب العظمى </strong><strong>(MDD)</strong><strong> وغيرها من الإضطرابات النفسية بأن مضادات الإكتئاب قد تزيد من خطورة الأفكار والسلوكات الإنتحارية في الأطفال والمراهقين والشباب مقارنة بالدواء الوهمي.</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;</strong><strong>أي شخص يفكر في استخدام سيتالوبرام أو أي من مضادات الاكتئاب الأخرى في الأطفال والمراهقين أو الشباب البالغين يجب عليه تحقيق التوازن بين هذه المخاطر مع الحاجة السريرية.</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;</strong><strong>لم تظهر الدراسات قصيرة المدى زيادة حالات الإنتحار عند استخدام مضادات الإكتئاب مقارنة بالدواء الوهمي في البالغين الذين تبلغ أعمارهم 24 سنة تقريبا؛ ولكنها أظهرت انخفاض في خطر الإنتحار عند استخدام مضادات الإكتئاب مقارنة بالدواء الوهمي في البالغين الذين تبلغ أعمارهم 65 سنة أو أكثر. يرتبط الإكتئاب أو الإصابة بأنواع معينة من الإضطرابات النفسية بزيادة خطر الإنتحار</strong></p><p dir="RTL"><strong>&nbsp;&nbsp;</strong><strong>- يجب القيام بمراقبة المرضى بشكل مناسب ومن جميع الأعمار الذين يتناولون العلاج المضاد للإكتئاب والقيام برصد دقيق لتفاقم الحالة السريرية، الانتحار، أو تغييرات غير عادية في السلوك.</strong></p><p dir="RTL"><strong>-&nbsp;</strong><strong>ينبغي نصح الأسر ومقدمي الرعاية للحاجة إلى مراقبة دقيقة للمريض والتواصل مع الطبيب.</strong></p><p dir="RTL"><strong>-&nbsp;لم تتم الموافقة على استخدام سيتالوبرام في المرضى من فئة الأطفال.</strong></p></td></tr></tbody></table></td></tr></tbody></table><p dir="RTL">عليك إخبار الطبيب إذا كنت تعاني من أي مشاكل طبية ، وخاصة إذا كنت تعاني من :</p><p dir="RTL">&middot;&nbsp;&nbsp; مرض في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp; مرض في الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp; داء السكري (قد تكون بحاجة إلى تعديل جرعة العلاج المضاد للسكري)</p><p dir="RTL">&middot;&nbsp;&nbsp; الصرع أو إذا كان لديك تاريخ إصابة بنوبات</p><p dir="RTL">&middot;&nbsp;&nbsp; اضطراب النزيف أو قد عانيت في أي وقت مضى من نزيف في المعدة أو الأمعاء</p><p dir="RTL">&middot;&nbsp;&nbsp; الخوف أو اضطرابات الهلع</p><p dir="RTL">&middot;&nbsp;&nbsp; إنخفاض معدل الصوديوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp; العلاج بالصدمات الكهربائية (ECT)</p><p dir="RTL">&middot;&nbsp;&nbsp; &nbsp;مشاكل في العينين، مثل الإصابة بأنواع معينة من الزرق</p><p dir="RTL">&middot;&nbsp;&nbsp; عانيت أو تعاني من مشاكل في القلب أو قد أصبت مؤخراً بأزمة قلبية.</p><p dir="RTL">&middot;&nbsp;&nbsp; انخفاض في نبض القلب عند الراحة و/ أو كنت على علم بأنه من الممكن أن يكون لديك نضوب في الأملاح نتيجة الإصابة بالإسهال لفترات طويلة أو القيء أو استخدام مدرات البول (أقراص الماء).</p><p dir="RTL">&middot;&nbsp;&nbsp; عانيت مسبقاً من نبض قلب غير طبيعي أو سريع، الإغماء، انهيارأو دوخة عند الوقوف والتي قد تشير إلى عمل غير طبيعي في معدل ضربات القلب.</p><p dir="RTL">يرجى إستشارة الطبيب، حتى إذا كنت قد عانيت من أحد هذه الحالات في أي وقت مضى.</p><p dir="RTL"><strong>يرجى الملاحظة:</strong></p><p dir="RTL">بعض المرضى الذين يعانون من مرض الهوس الإكتئابي قد يدخلون في مرحلة الهوس. وهذا يتمثل في عملية تغيير الأفكار بشكل سريع أو غير معتاد، سعادة غير لائقة ونشاط بدني مفرط. إذا واجهتك هذه الأعراض عليك التواصل مع الطبيب.</p><p dir="RTL">هناك بعض الأعراض التي من الممكن أن تعاني منها خلال الأسبوع الأول من العلاج مثل الشعور بعدم الراحة أو صعوبة عند الجلوس أو الوقوف. عليك اخبار الطبيب إذا واجهتك أحد هذه الأعراض.</p><p dir="RTL"><strong>معلومات خاصة تتعلق بإصابتك بالمرض</strong></p><p dir="RTL">كما هو الحال مع الأدوية الأخرى المستخدمة لعلاج الإكتئاب أو أمراض ذات الصلة، لا يتحقق التحسن فوراً من المرض. وكذلك فمن الممكن أن تشعر بالتحسن بعد مضي عدة أسابيع من البدء بتناول<strong> ليسيتال</strong>. في بداية العلاج بعض المرضى قد يعانون من زيادة القلق، الذي سوف يختفي خلال استمرار العلاج. وبالتالي، فمن المهم جدا أن تتبع أوامر الطبيب بالضبط ولا تتوقف عن العلاج أو تقوم بتغيير الجرعة دون استشارة الطبيب.</p><p dir="RTL"><strong>التفكير بالانتحار وتفاقم اضطراب القلق والإكتئاب </strong></p><p dir="RTL">إذا كنت تعاني من الإكتئاب و/ أواضطرابات القلق ففي بعض الأحيان قد تراودك أفكار حول إيذاء أو قتل نفسك. ومن الممكن أن تزداد هذه الأفكار عند البدء بتناول مضادات الإكتئاب لأول مرة، لأن كل هذه الأدوية تستغرق وقتا طويلا لبدء العمل، عادة حوالي أسبوعين وفي بعض الأحيان قد تمتد لفترة أطول.</p><p dir="RTL">قد تكون أكثر عرضة للتفكير على هذا النحو:</p><p dir="RTL">&bull; إذا راودتك أفكار سابقة حول قتل أو إيذاء نفسك.</p><p dir="RTL">&bull; إذا كنت من فئة الشباب البالغين. وقد أظهرت التجارب السريرية زيادة مخاطر السلوك الإنتحاري لدى البالغين الذين تقل أعمارهم عن 25 عاماً ويعانون من ظروف نفسية ويتعالجون باستخدام مضادات الإكتئاب.<br />إذا راودتك أفكار حول إيذاء أو قتل نفسك في أي وقت، فيجب عليك التواصل مع الطبيب أو الذهاب إلى المستشفى على الفور.</p><p dir="RTL">قد تجد أنه من المفيد أن تقوم بإخبار صديق أو قريب أنك تعاني من الإكتئاب أو اضطرابات القلق، وتطلب منهم أن يقوموا بقراءة هذه النشرة. قد تطلب منهم أيضاً أن يخبروك إذا اعتقدوا بأن حالة الإكتئاب أو القلق لديك قد أصبحت أكثر سوءاً، أو إذا كانو قلقين بشأن حدوث تغيرات على سلوكك.</p><p dir="RTL"><strong>استخدام ليسيتال في الأطفال أو المراهقين دون سن 18 سنة</strong></p><p dir="RTL">لا ينبغي عادة استخدام <strong>ليسيتال</strong> في الأطفال والمراهقين دون سن 18 عاماً. أيضا، يجب أن تكون على علم بأن المرضى الذين تقل أعمارهم عن 18 عام عندما يتناولون هذه الأدوية قد يزداد لديهم خطر الإصابة بآثار جانبية مثل محاولة الإنتحار، وأفكار انتحارية والعداء (في الغالب العدوان، وسلوك المعارضة والغضب). على الرغم من هذا، فمن الممكن أن يصف الطبيب سيتالوبرام للمرضى دون سن 18 سنة لأنه قد يرى أن تناولهم لهذا الدواء سيكون من مصلحتهم. إذا كان الطبيب قد وصف<strong> ليسيتال</strong> لمريض تحت سن 18 وكنت ترغب في مناقشة هذا الموضوع، يرجى الرجوع إلى الطبيب. كما يجب عليك إبلاغ الطبيب إذا كان أي من الأعراض المذكورة أعلاه قد ظهرت أو تفاقمت عند المرضى الذين تقل أعمارهم عن 18 عام ويتناولون <strong>ليسيتال</strong>. أيضا، لم يتم حتى الآن اثبات آثار السلامة عند تناول <strong>ليسيتال</strong> على المدى الطويل بشأن النمو والنضج والتطور المعرفي والسلوكي على هذه الفئة العمرية.</p><p dir="RTL"><strong>ج. تناول أدوية خرى:</strong></p><p dir="RTL">من الممكن أن تؤثر بعض الأدوية على عمل الأدوية الأخرى قد يتسبب أحيانا بردود فعل سلبية خطيرة. يرجى إخبار الطبيب أو الصيدلاني إذا كنت تتناول، قد تناولت أو قد تتناول أي أدوية أخرى. وهذا يشمل الأدوية الأخرى لعلاج الإكتئاب (انظر إلى بند لا تتناول <strong>ليسيتال</strong>).</p><p dir="RTL">&middot;&nbsp;&nbsp; نبتة سانت جون (هايبريكم بيرفوراتوم). لا ينبغي تناول هذه النبتة مع <strong>ليسيتال</strong> في نفس الوقت.</p><p dir="RTL">&middot;&nbsp;&nbsp; مثبطات أنزيم أحادي الأمين (MAOIs). لا ينبغي تناول هذه الأدوية مع <strong>ليسيتال</strong> في نفس الوقت (انظر إلى بند لا تتناول <strong>ليسيتال</strong>).</p><p dir="RTL">&middot;&nbsp;&nbsp; يجب عليك إخبار الطبيب إذا كنت تتناول أي من الأدوية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; لنزوليد (مضاد حيوي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; سوماتريبتان (المستخدم لعلاج الصداع النصفي) أو ترامادول (مسكن للألم). إذا كنت تشعر بعدم الراحة عند استخدام هذه الأدوية مع <strong>ليسيتال </strong>يجب عليك مراجعة الطبيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; ليثيوم (المستخدم لمنع حدوث الهوس وعلاجه) والتربتوفان (مضاد للإكتئاب).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; بيموزيد (مضاد للذهان). لا ينبغي تناوله مع <strong>ليسيتال</strong> في نفس الوقت.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إميبرامين وديسيبرامين (التي تستخدم لعلاج الإكتئاب).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; الأدوية التي تحتوي على سيليجيلين (المستخدمة لعلاج مرض باركنسون).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; سيميتيدين (المستخدم لعلاج قرحة المعدة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; المفلوكين (المستخدم لعلاج الملاريا).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; بوبروبيون (التي تستخدم لعلاج الاكتئاب).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; الأدوية المعروفة بتأثيرها على الصفائح الدموية (مثل مضادات التخثر المستخدمة لعلاج أو منع حدوث جلطات الدم، والأسبرين والأدوية غير الستيرويدية المضادة للإلتهابات(NSAIDs) ، مثل ايبوبروفين وديكلوفيناك المستخدمة كمسكنات للألم وبعض الأدوية المضادة للذهان ومضادات الإكتئاب ثلاثية الحلقات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; ميتوبرولول، وهو من حاصرات بيتا المستخدمة لعلاج الصداع النصفي، وبعض أمراض القلب وارتفاع ضغط الدم. آثار هذه الأدوية قد تزداد أو تنخفض أو تتغير.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; مضادات الذهان (المستخدمة لعلاج مرض انفصام الشخصية).</p><p dir="RTL">لا تتناول<strong> ليسيتال</strong> إذا كنت تتناول أدوية لعلاج مشاكل ضربات القلب أو أدوية من الممكن أن تؤثر على نبض القلب، على سبيل المثال، مضادات اضطراب النظم فئة IA و III، مضادات الذهان (مثل مشتقات الفينوثيازين، بيموزيد، هالوبيريدول)، مضادات الإكتئاب ثلاثية الحلقات، وبعض المضادات الحيوية (على سبيل المثال سبارفلوكساسين، موكسيفلوكساسين، اريثروميسين IV، بنتاميدين، الأدوية المستخدمة لعلاج الملاريا خاصة هالوفانترين)، وبعض مضادات الهيستامين (استيميزول، ميزولاستين). إذا كان لديك أي أسئلة أخرى حول هذا يجب عليك التواصل مع الطبيب.</p><p dir="RTL"><strong>د. تناول ليسيتال مع الطعام، الشراب والكحول:</strong></p><p dir="RTL">من الممكن أن تتناول <strong>ليسيتال</strong> مع الطعام أو بدونه (انظر إلى بند 3 &quot; كيفية تناول <strong>ليسيتال</strong>&quot;).</p><p dir="RTL">كما هو الحال مع جميع مضادات الإكتئاب، فمن المنطقي أن تتجنب شرب الكحول أثناء تلقي العلاج على الرغم من أن<strong> ليسيتال</strong> لم يظهر أي زيادة على تأثير الكحول.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ه. الحمل والإرضاع والخصوبة:</strong></p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">يجب عليك استشارة الطبيب أو الصيدلاني قبل تناول أي دواء. إذا كنت حامل أوتعتقدين أنك حامل أو تخططين للإنجاب، فيجب عليك اخبار الطبيب بذلك. فإذا كنت حامل لا تتناولي<strong> ليسيتال</strong> إلا إذا كنت قد تناقشتي مع الطبيب حول مخاطر ومنافع هذا الدواء.</p><p dir="RTL">تأكدي أن تكون القابلة و/ أو الطبيب على علم بأنك قمت بتناول<strong> ليسيتال</strong> خلال فترة الحمل، خاصة خلال الثلاث أشهر الأخيرة من الحمل، لأن الأدوية مثل <strong>ليسيتال</strong> من الممكن أن تزيد من إصابة حديثي الولادة بحالة مرضية حرجة، تدعى ارتفاع ضغط الدم الرئوي المستمر في حديثي الولادة (PPHN)، مما يجعل الطفل يتنفس بشكل أسرع ويكون مزرق اللون. وعادة ما تبدأ هذه الأعراض بالظهور خلال الـ 24 ساعة الأولى بعد الولادة. إذا حدث هذا لطفلك يجب عليك التواصل مع القابلة أو/ و الطبيب على الفور. أيضا، إذا قمت بتناول <strong>ليسيتال</strong> خلال الثلاث أشهر الأخيرة من الحمل وحتى تاريخ الولادة يجب أن تكون على علم بأن التأثيرات التالية من الممكن أن تظهر في الأطفال حديثي الولادة: نوبات، الشعور بالحر أو البرد، صعوبة في الرضاعة، التقيؤ، انخفاض نسبة السكر في الدم، تصلب أو مرونة في العضلات، ردود فعل مفرطة، رعاش، العصبيه، التهيج، الخمول، البكاء المستمر، النعاس أو صعوبة في النوم. إذا كان طفلك حديث الولادة يعاني من أحد هذه الأعراض فيجب عليك التواصل مع القابلة و/ أو الطبيب على الفور.</p><p dir="RTL"><u>الإرضاع</u></p><p dir="RTL">يجب عليك استشارة الطبيب أو الصيدلاني قبل تناول أي دواء. إذا كنت مرضع، قومي بطلب النصيحة من الطبيب. يجب عليك عدم إرضاع طفلك عند تناول<strong> ليسيتال </strong>لأنه من الممكن أن تنتقل كميات صغيرة من الدواء إلى حليب الثدي.</p><p dir="RTL"><u>الخصوبة</u></p><p dir="RTL">وقد أظهرت الدراسات التي تم إجرائها على الحيوانات أن سيتالوبرام يحد من جودة الحيوانات المنوية. من الناحية النظرية، فإن هذا من الممكن أن &nbsp;يؤثر على الخصوبة، ولكن حتى الآن لم يلاحظ تأثيره على الخصوبة البشرية.</p><p dir="RTL"><strong>و. القيادة واستخدام الآلات:</strong></p><p dir="RTL">لا يؤثر <strong>ليسيتال </strong>عادة على قدرتك للقيام بالأنشطة اليومية العادية. ومع ذلك، إذا كنت تشعر بالدوار أو النعاس عند البدء بتناول هذا الدواء، يجب أن تكون حذراً عند القيادة، تشغيل الآلات أو أداء الوظائف التي تحتاج منك أن تكون في حالة تأهب حتى زوال هذه الآثار الجانبية.</p><p dir="RTL"><strong>ز. معلومات مهمة عن بعض مكونات ليسيتال:</strong></p><p dir="RTL">يحتوي هذا الدواء على اللاكتوز، فإذا أخبرك الطبيب بأنك من الممكن أن لا تتحمل بعض السكريات، قم بالتواصل مع الطبيب قبل تناولك لهذا الدواء.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائماً بتناول هذا الدواء تماماً كما أخبرك الطبيب أو الصيدلاني. إذا كنت غير متأكد بإمكانك الرجوع الى الطبيب أو الصيدلاني.</p><p dir="RTL"><strong>البالغين</strong></p><p dir="RTL"><u>الإكتئاب</u></p><p dir="RTL">عادة تكون الجرعة 20 ملغم يومياً. ومن الممكن أن يقوم الطبيب بزيادة الجرعة لتصل كحد أقصى إلى 40 ملغم يومياً.</p><p dir="RTL"><u>اضطراب الهلع</u></p><p dir="RTL">تكون جرعة البدء 10 ملغم يومياً خلال الأسبوع الأول وبعد ذلك يتم زيادة الجرعة لتصل إلى 20-30 ملغم يومياً. ومن الممكن أن يقوم الطبيب بزيادة الجرعة لتصل كحد أقصى إلى 40 ملغم يومياً.</p><p dir="RTL"><strong>كبار السن (أعمارهم تتجاوز 65 عام)</strong></p><p dir="RTL">يجب إنقاص جرعة البدء لتكون نصف الجرعة الموصى بها، مثلاً: 10-20 ملغم يومياً. عادة لا يجب إعطاء كبار السن جرعة أكثر من 20 ملغم يومياً.</p><p dir="RTL"><strong>الأطفال والمراهقين (أعمارهم أقل من 18عام)</strong></p><p dir="RTL">لا يجب تناول <strong>ليسيتال</strong> من قبل الأطفال والمراهقين. لمزيد من المعلومات، يرجى الرجوع إلى بند 2، قبل تناول <strong>ليسيتال</strong>.</p><p dir="RTL"><strong>المرضى الذين لديهم مخاطر خاصة</strong></p><p dir="RTL">المرضى الذين يعانون من مشاكل في الكبد لا ينبغي أن يتناولون أكثر من 20 ملغم يومياً.</p><p dir="RTL"><strong>متى وكيف يؤخذ ليسيتال</strong></p><p dir="RTL">يتم تناول <strong>ليسيتال</strong> كجرعة واحدة يومياً. ومن الممكن تناول<strong> ليسيتال</strong> في أي وقت من اليوم مع الطعام أو بدونه. يجب ابتلاع قرص الدواء مع كأس من الماء. لا تقم بمضغ الأقراص (لأنها مرة المذاق).</p><p dir="RTL"><strong>مدة العلاج</strong></p><p dir="RTL">مثل غيره من الأدوية المضادة للإكتئاب واضطرابات الهلع من الممكن أن تنقضي عدة أسابيع على استخدام <strong>ليسيتال </strong>دون الشعور بأي تحسن. ولكن عليك الإستمرار بتناول<strong> ليسيتال</strong> حتى لو استغرق ذلك بعض الوقت قبل الشعور بالتحسن في حالتك. تتفاوت مدة العلاج من شخص لآخر، وعادة تكون على الأقل 6 أشهر. استمر بتناول هذه الأقراص على طول المدة التي أوصى بها الطبيب. لا تتوقف عن تناولها إذا شعرت بالتحسن، إلا إذا أخبرك الطبيب بذلك. قد يستمر هذا المرض لفترة طويلة وإذا توقفت عن العلاج في وقت مبكر قد تعود أعراض المرض للظهور ثانية.</p><p dir="RTL">المرضى الذين تتكرر لديهم حالات الإكتئاب يستفيدون من الإستمرار في العلاج، وأحيانا لعدة سنوات، لمنع حدوث نوبات اكتئاب جديدة.</p><p dir="RTL">لا تقم نهائيا بتغيير جرعة الدواء الخاصة بك قبل أن تتحدث مع الطبيب أولاً.</p><p dir="RTL"><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا كنت تتناول جرعة ليسيتال أكثر من اللازم:</strong></p><p dir="RTL">إذا كنت تعتقد أنك تناولت الكثير من أقراص <strong>ليسيتال</strong> أو أي شخص آخر قد قام بذلك&nbsp; فيجب أن تتواصل مع الطبيب أو أقرب قسم طوارئ في المستشفى على الفور. يجب عليك القيام بذلك حتى إذا لم تكن هناك أي علامات من عدم الراحة أو التسمم. وقم باصطحاب علبة الدواء معك عند ذهابك إلى الطبيب أو المستشفى. بعض علامات فرط الجرعة قد تكون مهددة للحياة.</p><p dir="RTL">ويمكن أن تشمل أعراض فرط الجرعة:</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp; ضربات قلب غير منتظمة</p><p dir="RTL">&middot;&nbsp;&nbsp; نوبات صرع</p><p dir="RTL">&middot;&nbsp;&nbsp; التغييرات في ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp; الشعور بالمرض (غثيان)</p><p dir="RTL">&middot;&nbsp;&nbsp; التقيؤ</p><p dir="RTL">&middot;&nbsp;&nbsp; التعرق</p><p dir="RTL">&middot;&nbsp;&nbsp; نعاس</p><p dir="RTL">&middot;&nbsp;&nbsp; فقدان الوعي</p><p dir="RTL">&middot;&nbsp;&nbsp; دقات قلب سريعة</p><p dir="RTL">&middot;&nbsp;&nbsp; رعاش</p><p dir="RTL">&middot;&nbsp;&nbsp; تغييرات في ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp; متلازمة السيروتونين (انظر إلى بند 4)</p><p dir="RTL">&middot;&nbsp;&nbsp; تهيج</p><p dir="RTL">&middot;&nbsp;&nbsp; دوخة</p><p dir="RTL">&middot;&nbsp;&nbsp; اتساع حدقة العين</p><p dir="RTL">&middot;&nbsp;&nbsp; الجلد المزرق.</p><p dir="RTL">&middot;&nbsp;&nbsp; التنفس بسرعة كبيرة جداً</p><p dir="RTL"><strong>ب.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا نسيت أن تتناول ليسيتال:</strong></p><p dir="RTL">إذا نسيت تناول الجرعة، قم بتناول الجرعة التالية في الوقت المعتاد. لا تتناول جرعة مضاعفة.</p><p dir="RTL"><strong>ج&zwnj;.&nbsp;&nbsp; </strong><strong>إذا توقفت عن تناول ليسيتال:</strong></p><p dir="RTL">قد يسبب التوقف بسرعة عن تناول هذا الدواء إلى الإصابة بأعراض مثل الدوار، الغثيان وخدر أو وخز في اليدين أو القدمين، اضطرابات النوم (أحلام اليقظة، كوابيس، عدم القدرة على النوم)، الشعور بالقلق، الصداع والشعور بالمرض، تعرق، الشعور بعدم الراحة أو التهيج، رعاش، الشعور بالإرتباك، الشعور العاطفي أو الانفعال، إسهال، اضطرابات بصرية، رفة أو خفقان في ضربات القلب. وتكون بالعادة غير خطيرة وتختفي خلال عدة أيام. عند انتهاء العلاج، عادة ما يتم تقليل جرعة <strong>ليسيتال</strong> تدريجياً خلال أسبوعين.</p><p dir="RTL"><strong>إذا كان لديك أي استفسارات أخرى حول استخدام هذا الدواء، قم بسؤال الطبيب أو الصيدلاني.</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب آثار جانبية على الرغم من عدم حدوثها لدى الجميع. العديد من الآثار الجانبية الواردة أدناه يمكن&nbsp; أن تكون أعراض المرض ومن الممكن أن تختفي عندما تبدأ بالشعور بالتحسن.</p><p dir="RTL"><strong>آثار جانبية خطيرة</strong></p><p dir="RTL">توقف عن تناول<strong> ليسيتال </strong>وقم بطلب المشورة الطبية فوراً، إذا كنت تعاني من أحد هذه الأعراض:</p><p dir="RTL">&middot;&nbsp;&nbsp; صعوبة في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp; تورم في الوجه، الشفاه، اللسان أو الحلق الذي من الممكن أن يسبب صعوبة في البلع أو التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp; حكة شديدة في الجلد (مع ظهور تورمات).</p><p dir="RTL">&middot;&nbsp;&nbsp; نبضات قلب سريعة ، أو غير منتظمة، إغماء وهي من الممكن أن تكون أعراض حالة مهددة للحياة تدعى torsades de pointes</p><p dir="RTL">إذا لاحظت أي من الأعراض التالية يجب عليك التواصل مع الطبيب على الفور لأنه من الممكن أن تكون بحاجة إلى خفض الجرعة أو التوقف عن تناول الدواء:</p><p dir="RTL">&middot;&nbsp;&nbsp; بدأت تعاني من نوبات لأول مرة أو النوبات التي كنت تعاني منها مسبقاً قد أصبحت أكثر تكراراً.</p><p dir="RTL">&middot;&nbsp;&nbsp; تغييرات على سلوكك بسبب الشعور بالبهجة أو فرط الحماس.</p><p dir="RTL">&middot;&nbsp;&nbsp; أصبت بحمى شديدة، تهيج، ارتباك، رجفة أو تقلصات مفاجئة للعضلات. وهذه قد تكون دلائل على وجود حالة نادرة تدعى بمتلازمة السيروتونين.</p><p dir="RTL">&middot;&nbsp;&nbsp; التعب، الارتباك وارتعاش العضلات. وهذه قد تكون علامات على خفض مستوى الصوديوم في الدم (نقص صوديوم الدم).</p><p dir="RTL">إذا راودتك أي أفكار حول إيذاء أو قتل نفسك في أي وقت، قم بالتواصل مع الطبيب أو قم بالذهاب إلى المستشفى على الفور.</p><p dir="RTL">الآثار الجانبية التالية غالبا ما تكون خفيفة وتختفي عادة بعد البدأ بالعلاج ببضعة أيام.</p><p dir="RTL"><strong>الآثار الجانبية الأكثر شيوعاً ( من الممكن أن تصيب أكثر من شخص لكل 10 أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; النعاس</p><p dir="RTL">&middot;&nbsp;&nbsp; صعوبة في النوم</p><p dir="RTL">&middot;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp; تغيير في نمط النوم الخاص بك</p><p dir="RTL">&middot;&nbsp;&nbsp; فقدان قوة الجسم، ضعف</p><p dir="RTL">&middot;&nbsp;&nbsp; زيادة التعرق</p><p dir="RTL">&middot;&nbsp;&nbsp; جفاف الفم (جفاف الفم يزيد من مخاطر تسوس الأسنان، لذا يجب التأكد من تنظيف أسنانك أكثر من المعتاد)</p><p dir="RTL">&middot;&nbsp;&nbsp; الشعور بالمرض (الغثيان)</p><p dir="RTL"><strong>الآثار الجانبية الشائعة ( من الممكن أن تصيب لغاية شخص لكل 10 أشخاص)</strong><strong> </strong></p><p dir="RTL">&middot;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp; التهيج</p><p dir="RTL">&middot;&nbsp;&nbsp; انخفاض الدافع الجنسي</p><p dir="RTL">&middot;&nbsp;&nbsp; القلق</p><p dir="RTL">&middot;&nbsp;&nbsp; العصبية</p><p dir="RTL">&middot;&nbsp;&nbsp; الارتباك</p><p dir="RTL">&middot;&nbsp;&nbsp; أحلام غير طبيعية</p><p dir="RTL">&middot;&nbsp;&nbsp; نقص عاطفي، واللامبالاة.</p><p dir="RTL">&middot;&nbsp;&nbsp; الرعاش</p><p dir="RTL">&middot;&nbsp;&nbsp; وخز أو خدر في اليدين أو القدمين</p><p dir="RTL">&middot;&nbsp;&nbsp; دوخة</p><p dir="RTL">&middot;&nbsp;&nbsp; مشاكل في التركيز</p><p dir="RTL">&middot;&nbsp;&nbsp; صداع نصفي</p><p dir="RTL">&middot;&nbsp;&nbsp; فقدان الذاكرة (النسيان)</p><p dir="RTL">&middot;&nbsp;&nbsp; رنين في الأذنين (الطنين)</p><p dir="RTL">&middot;&nbsp;&nbsp; الخفقان</p><p dir="RTL">&middot;&nbsp;&nbsp; التثاؤب</p><p dir="RTL">&middot;&nbsp;&nbsp; انسداد أو سيلان الأنف (التهاب الأنف)</p><p dir="RTL">&middot;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp; التقيؤ</p><p dir="RTL">&middot;&nbsp;&nbsp; إمساك</p><p dir="RTL">&middot;&nbsp;&nbsp; ألم في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp; انتفاخ (ريح)</p><p dir="RTL">&middot;&nbsp;&nbsp; زيادة في افراز اللعاب (الترويل)</p><p dir="RTL">&middot;&nbsp;&nbsp; حكة</p><p dir="RTL">&middot;&nbsp;&nbsp; ألم في العضلات والمفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp; بالنسبة للرجال، مشاكل في القذف والانتصاب</p><p dir="RTL">&middot;&nbsp;&nbsp; بالنسبة للنساء، فشل في الوصول إلى هزة الجماع</p><p dir="RTL">&middot;&nbsp;&nbsp; التعب</p><p dir="RTL">&middot;&nbsp;&nbsp; وخز في الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL"><strong>آثار جانبية غير شائعة (من الممكن أن تصيب لغاية شخص لكل 100 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; سهولة الإصابة بالكدمات.</p><p dir="RTL">&middot;&nbsp;&nbsp; زيادة الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp; العدوان</p><p dir="RTL">&middot;&nbsp;&nbsp; الهلوسة</p><p dir="RTL">&middot;&nbsp;&nbsp; هوس</p><p dir="RTL">&middot;&nbsp;&nbsp; الإغماء</p><p dir="RTL">&middot;&nbsp;&nbsp; اتساع حدقة العين (بؤبؤ العين)</p><p dir="RTL">&middot;&nbsp;&nbsp; ضربات قلب سريعة</p><p dir="RTL">&middot;&nbsp;&nbsp; بطء في ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp; الطفح الجلدي القارص</p><p dir="RTL">&middot;&nbsp;&nbsp; فقدان الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp; الحساسية ضد أشعة الشمس</p><p dir="RTL">&middot;&nbsp;&nbsp; صعوبة في التبول</p><p dir="RTL">&middot;&nbsp;&nbsp; نزيف الطمث المفرط</p><p dir="RTL">&middot;&nbsp;&nbsp; تورم في الذراعين أو الساقين</p><p dir="RTL">&middot;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL"><strong>الآثار الجانبية النادرة (من الممكن أن تصيب لغاية شخص لكل 1000 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; زيادة الدافع الجنسي</p><p dir="RTL">&middot;&nbsp;&nbsp; التشنجات</p><p dir="RTL">&middot;&nbsp;&nbsp; الحركات اللاإرادية</p><p dir="RTL">&middot;&nbsp;&nbsp; اضطرابات التذوق</p><p dir="RTL">&middot;&nbsp;&nbsp; نزيف</p><p dir="RTL">&middot;&nbsp;&nbsp; السعال</p><p dir="RTL">&middot;&nbsp;&nbsp; التهاب الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp; الشعور بالإعياء (الضيق)</p><p dir="RTL">آثار جانبية قد تم تسجيلها من قبل بعض المرضى (معدل تكرار حدوثها غير معروف)</p><p dir="RTL">&middot;&nbsp; اعتقادات بشأن ايذاء أو قتل أنفسهم، انظر أيضاً إلى بند 2&nbsp; &quot;قبل تناول <strong>ليسيتال</strong>&quot;</p><p dir="RTL">&middot;&nbsp; زيادة في النزيف أو الكدمات الناجمة عن انخفاض في الصفائح الدموية (الصفيحات)</p><p dir="RTL">&middot;&nbsp; طفح جلدي (فرط الحساسية)</p><p dir="RTL">&middot;&nbsp; انخفاض مستويات البوتاسيوم في الدم (نقص بوتاسيوم الدم)، الذي يمكن أن يسبب ضعف العضلات، والشعور بالوخز أو عدم انتظام ضربات القلب</p><p dir="RTL">&middot;&nbsp; نوبة الهلع</p><p dir="RTL">&middot;&nbsp; طحن أو صك الأسنان</p><p dir="RTL">&middot;&nbsp; الأرق</p><p dir="RTL">&middot;&nbsp; حركات غير عادية أو تصلب في العضلات</p><p dir="RTL">&middot;&nbsp; حركات لا إرادية للعضلات (تعذر الجلوس)</p><p dir="RTL">&middot;&nbsp; ضغط دم منخفض</p><p dir="RTL">&middot;&nbsp; النزيف الأنفي</p><p dir="RTL">&middot;&nbsp; اضطرابات النزيف بما في ذلك نزيف من الجلد والغشاء المخاطي (كدمة)</p><p dir="RTL">&middot;&nbsp; تورم مفاجئ في الجلد أو الغشاء المخاطي</p><p dir="RTL">&middot;&nbsp; بالنسبة للرجال، انتصاب مؤلم</p><p dir="RTL">&middot;&nbsp; تدفق حليب الثدي عند الرجال أو في النساء غير المرضعات (ادرار الحليب)</p><p dir="RTL">&middot;&nbsp; دورة شهرية غير منتظمة</p><p dir="RTL">&middot;&nbsp; نتائج غير طبيعية لاختبارات وظائف الكبد</p><p dir="RTL">&middot;&nbsp; وقد لوحظ زيادة خطر كسور العظام في المرضى الذين يتناولون هذا النوع من الأدوية</p><p dir="RTL">&middot;&nbsp; ضربات قلب غير طبيعية</p><p dir="RTL">من الممكن أن تسبب الـ SSRIs وبشكل نادر جداً، زيادة خطر النزيف، بما في ذلك نزيف في المعدة أو الأمعاء. قم بإخبار الطبيب إذا كنت تتقيء دم أو كنت تعاني من براز أسود اللون أو ملطخ بالدماء.</p><p dir="RTL">كما أنه يجب عليك إخبار الطبيب إذا ما زلت تعاني من أعراض أخرى مرتبطة بالإكتئاب. ويمكن أن تشمل الهلوسة والقلق والهوس أو الارتباك.</p><p dir="RTL"><strong>إ</strong><strong>ذا زادت حدة أحد هذه الأعراض الجانبية، أو لاحظت أي أعراض جانبية لم يرد ذكرها في هذه النشرة، يرجى اخبار الطبيب أو الصيدلي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp; يحفظ بعيدا عن متناول الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp; لا تستخدم <strong>ليسيتال</strong> بعد انتهاء فترة الصلاحية&nbsp; المذكورة على اللاصق الداخلي و العبوة الخارجية.</p><p dir="RTL">&middot;&nbsp;&nbsp; لا يحتاج هذا المنتج الطبي الى ظروف تخزين خاصة.</p><p dir="RTL">&middot;&nbsp;&nbsp; لا تستخدم <strong>ليسيتال </strong>عند ملاحظة أي علامة تلف عليه.</p><p dir="RTL">&middot;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ليسيتال 20</strong><strong> </strong><strong>&nbsp;</strong>يحتوي على 20 ملغم من سيتالوبرام (على هيئة هيدروبرومايد).</p><p dir="RTL"><strong>ليسيتال 40</strong><strong> </strong><strong>&nbsp;</strong>يحتوي على 40 ملغم من سيتالوبرام (على هيئة هيدروبرومايد).</p><p dir="RTL">المكونات الأخرى هي: نشاء الذرة/ بوفيدون/ كروسكارميللوز/ لاكتوز مونوهايدريت/ مايكروكريستالين سيليولوز 101/ مايكروكريستالين سيليولوز 102/ ثنائي أكسيد السيليكون الغروية / مغنيسيوم ستيريت/ لستر كلير (مايكروكريستالين سيليولوز، كاراجينان، كلايجول متعدد الايثيلين)/ ثنائي أكسيد التيتانيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشكل الصيدلاني: أقراص مغلفة غشائياً.</p><p dir="RTL">سعة عبوة <strong>ليسيتال 20: </strong>30 قرص مغلف غشائيا.</p><p dir="RTL">سعة عبوة <strong>ليسيتال 40: </strong>30 قرص مغلف غشائيا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشركة الأردنية السويدية للمنتجات الطبية و التعقيم.</p><p dir="RTL">صندوق بريد 851831&nbsp; عمان 11185&nbsp; الأردن</p><p dir="RTL">الايميل: joswe@go.com.jo</p><p dir="RTL">www.joswe.com</p><p dir="RTL">هاتف:&nbsp; 96265859765+ , 96265728327+&nbsp;</p><p dir="RTL">فاكس: 96265814526+&nbsp; ,96265728326+</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في 02/2017؛ رقم المراجعة R2
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lecital 20mg Film-coated Caplets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lecital 20 F.C Caplet: Each film-coated caplet contains 20mg Citalopram.
Excipient(s) with known effect:
Lecital 20mg film-coated caplet contains lactose monohydrate.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated caplet.
Lecital 20 F.C Caplet: White to Off-White flat film coated Caplet, bisected from one side and embossed with Lecital from the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of depressive illness in the initial phase and as maintenance against potential relapse/recurrence.<br />Lecital/ Citalopram is also indicated in the treatment of panic disorder with or without agoraphobia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>UPosology<br />Major Depressive Episodes<br />Adults:<br />Citalopram should be administered as a single oral dose of 20 mg daily. Dependent on individual patient response, the dose may be increased to a maximum of 40 mg daily. In general, improvement in patients starts after one week, but may only become evident from the second week of therapy.<br />As with all antidepressant medicinal products, dosage should be reviewed and adjusted, if necessary, within 3 to 4 weeks of initiation of therapy and thereafter as judged clinically appropriate. Although there may be an increased potential for undesirable effects at higher doses, if after some weeks on the recommended dose insufficient response is seen, some patients may benefit from having their dose increased up to a maximum of 40 mg a day (see section 5.1). Dosage adjustments should be made carefully on an individual patient basis, to maintain the patient at the lowest effective dose.<br />Patients with depression should be treated for a sufficient period of at least 6 months to ensure that they are free from symptoms.</p><p>Panic Disorder<br />Adults:<br />A single oral dose of 10 mg is recommended for the first week before increasing the dose to 20 mg daily. Dependent on individual patient response, the dose may be increased to a maximum of 40 mg daily.</p><p>Patients should be started on 10 mg/day and the dose gradually increased in 10 mg steps according to the patient&#39;s response up to the recommended dose. A low initial starting dose is recommended to minimise the potential worsening of panic symptoms, which is generally recognised to occur early in the treatment of this disorder. Although there may be an increased potential for undesirable effects at higher doses, if after some weeks on the recommended dose insufficient response is seen some patients may benefit from having their dose increased gradually up to a maximum of 40 mg/day (see section 5.1). Dosage adjustments should be made carefully on an individual patient basis, to maintain the patients at the lowest effective dose.</p><p>Patients with panic disorder should be treated for a sufficient period to ensure that they are free from symptoms. This period may be several months or even longer.</p><p>Elderly patients (&gt; 65 years of age)<br />For elderly patients the dose should be decreased to half of the recommended dose, e,g, 10-20 mg daily. The recommended maximum dose for the elderly is 20 mg daily.</p><p>Children and adolescents (&lt; 18 years of age)<br />Citalopram should not be used in the treatment of children and adolescents under the age of 18 years (see section 4.4).</p><p>Reduced hepatic function<br />An initial dose of 10 mg daily for the first two weeks of treatment is recommended in patients with mild or moderate hepatic impairment. Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily. Caution and extra careful dose titration is advised in patients with severely reduced hepatic function (see section 5.2).</p><p>Reduced renal function<br />Dosage adjustment is not necessary in cases of mild or moderate renal impairment. No information is available in cases of severe renal impairment (creatinine clearance &lt;20 mL / min).</p><p>Poor metabolisers of CYP2C19<br />An initial dose of 10 mg daily during the first two weeks of treatment is recommended for patients who are known to be poor metabolisers with respect to CYP2C19. The dose may be increased to a maximum of 20 mg daily depending on individual patient response (see section 5.2).</p><p>Withdrawal symptoms seen on discontinuation of citalopram<br />Abrupt discontinuation should be avoided. When stopping treatment with citalopram the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal reactions (see section 4.4 Special Warnings and Precautions for Use and section 4.8 Undesirable Effects). If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.</p><p>Method of administration<br />Citalopram Caplets are administered as a single daily dose. Citalopram Caplets can be taken at any time of the day without regard to food intake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Monoamine Oxidase Inhibitors (MAOIs)
Some cases presented with features resembling serotonin syndrome.
Citalopram should not be given to patients receiving MAOIs, including selegiline, in daily doses exceeding 10 mg/day.
Citalopram should not be given for fourteen days after discontinuation of an irreversible MAOI or for the time specified after discontinuation of a reversible MAOI (RIMA) as stated in the prescribing text of the RIMA.
MAOIs should not be introduced for seven days after discontinuation of citalopram (see section 4.5).
Citalopram is contraindicated in combination with linezolid unless there are facilities for close observation and monitoring of blood pressure (see section 4.5).
Citalopram is contraindicated in patients with known QT-interval prolongation or congenital long QT syndrome.
Citalopram is contraindicated together with medicinal products that are known to prolong the QT-interval (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="1" cellpadding="1" style="width:1349px"><tbody><tr><td style="width:1346px"><p>Suicidality and Antidepressant Drugs:</p><p>- Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders.</p><p>- Anyone considering the use of Citalopram or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need.</p><p>- Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide.</p><p>- Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior.</p><p>- Families and caregivers should be advised of the need for close observation and communication with the prescriber.</p><p>- Citalopram is not approved for use in pediatric patients.</p></td></tr></tbody></table><p>Suicide/suicidal thoughts or clinical worsening</p><p>Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.</p><p>Other psychiatric conditions for which Lecital is prescribed can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders.</p><p>Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.</p><p>Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.</p><p>Use in children and adolescents under 18 years of age</p><p>Lecital should not be used in the treatment of children and adolescents under the age of 18 years. Suicide-related behaviours (suicide attempt and suicidal thoughts) and hostility (predominantly aggression, oppositional behaviour and anger) were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated with placebo. If, based on clinical need, a decision to treat is nevertheless taken; the patient should be carefully monitored for the appearance of suicidal symptoms.</p><p>In addition, long-term safety data in children and adolescents concerning growth, maturation and cognitive and behavioural development are lacking.</p><p>Elderly patients<br />Caution should be used in the treatment of elderly patients (see section 4.2).</p><p>Reduced kidney and liver function<br />Caution should be used in the treatment of patients with reduced kidney and liver function (see section 4.2).</p><p>Paradoxical anxiety<br />Some patients with panic disorder may experience intensified anxiety symptoms at the start of treatment with antidepressants. This paradoxical reaction usually subsides within the first two weeks of starting treatment. A low starting dose is advised to reduce the likelihood of a paradoxical anxiogenic effect (see section 4.2).</p><p>Hyponatraemia<br />Hyponatraemia, probably due to inappropriate antidiuretic hormone secretion (SIADH), has been reported as a rare adverse reaction with the use of SSRIs and generally reverses on discontinuation of therapy. Elderly female patients seem to be at particularly high risk.</p><p>Akathisia/psychomotor restlessness<br />The use of SSRIs/SNRIs has been associated with the development of akathisia, characterised by a subjectively unpleasant or distressing restlessness and need to move often accompanied by an inability to sit or stand still. This is most likely to occur within the first few weeks of treatment. In patients who develop these symptoms, increasing the dose may be detrimental.</p><p>Mania<br />In patients with manic-depressive illness a change towards the manic phase may occur. Should the patient enter a manic phase citalopram should be discontinued.</p><p>Seizures<br />Seizures are a potential risk with antidepressant drugs. Citalopram should be discontinued in any patient who develops seizures. Citalopram should be avoided in patients with unstable epilepsy and patients with controlled epilepsy should be carefully monitored. Citalopram should be discontinued if there is an increase in seizure frequency.</p><p>Diabetes<br />In patients with diabetes, treatment with an SSRI may alter glycaemic control. Insulin and/or oral hypoglycaemic dosage may need to be adjusted.</p><p>Angle-closure Glaucoma<br />SSRIs including citalopram may have an effect on pupil size resulting in mydriasis. This mydriatic effect has the potential to narrow the eye angle resulting in increased intraocular pressure and angle-closure glaucoma, especially in patients pre-disposed. Citalopram should therefore be used with caution in patients with angle-closure glaucoma or history of glaucoma.</p><p>Serotonin syndrome<br />In rare cases, serotonin syndrome has been reported in patients using SSRIs. A combination of symptoms such as agitation, tremor, myoclonus and hyperthermia may indicate the development of this condition (see section 4.5). Treatment with citalopram should be discontinued immediately and symptomatic treatment initiated.</p><p>Serotonergic medicinesU<br />Citalopram should not be used concomitantly with medicinal products with serotonergic effects such as sumatriptan or other triptans, tramadol, oxitriptan and tryptophan.</p><p>Haemorrhage<br />There have been reports of prolonged bleeding time and /or bleeding abnormalities such as ecchymoses, gynaecological haemorrhages, gastrointestinal bleeding and other cutaneous or mucous bleedings with SSSRIs (see section 4.8). Caution is advised in patients taking SSRIs, particularly with concomitant use of active substances known to affect platelet function or other active substances that can increase the risk of haemorrhage, as well as in patients with a history of bleeding disorders (see section 4.5).</p><p>ECT&nbsp;(electroconvulsive therapy)<br />There is limited clinical experience of concurrent administration of SSRIs and ECT; therefore caution is advisable.</p><p>Reversible, selective MAO-A inhibitors<br />For information on concomitant treatment with non-selective, irreversible MAO-inhibitors see section 4.5.</p><p>St. John&#39;s wort<br />Undesirable effects may be more common during concomitant use of citalopram and herbal preparations containing St John&#39;s wort (Hypericum perforatum). Therefore citalopram and St John&#39;s wort preparations should not be taken concomitantly (see section 4.5).</p><p>Withdrawal symptoms seen on discontinuation of SSRI treatment<br />Withdrawal symptoms when treatment is discontinued are common, particularly if discontinuation is abrupt (see section 4.8 Undesirable effects). In a recurrence prevention clinical trial with citalopram, adverse events after discontinuation of active treatment were seen in 40% patients versus 20% in patients continuing citalopram.</p><p>The risk of withdrawal symptoms may be dependent on several factors including the duration and dose of therapy and the rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor, confusion, sweating, headache, diarrhoea, palpitations, emotional instability, irritability, and visual disturbances are the most commonly reported reactions. Generally these symptoms are mild to moderate, however, in some patients they may be severe in intensity. They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose. Generally these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2-3 months or more). It is therefore advised that citalopram should be gradually tapered when discontinuing treatment over a period of several weeks or months, according to the patient&#39;s needs (see &ldquo;Withdrawal symptoms seen on discontinuation of citalopram&rdquo;, Section 4.2).</p><p>Psychosis<br />Treatment of psychotic patients with depressive episodes may increase psychotic symptoms.</p><p>QT-interval prolongation<br />Citalopram has been found to cause a dose-dependent prolongation of the QT-interval. Cases of QT interval prolongation and ventricular arrhythmia including torsade de pointes have been reported during the post-marketing period, predominantly in patients of female gender, with hypokalaemia, or with pre-existing QT prolongation or other cardiac diseases (see sections 4.3, 4.5, 4.8, 4.9 and 5.1).<br />Caution is advised in patients with significant bradycardia; or in patients with recent acute myocardial infarction or uncompensated heart failure.</p><p>Electrolyte disturbances such as hypokalaemia and hypomagnesaemia increase the risk for malignant arrhythmias and should be corrected before treatment with citalopram is started.</p><p>If patients with stable cardiac disease are treated, an ECG review should be considered before treatment is started.<br />ECG monitoring may be advisable in case of overdose or conditions of altered metabolism with increased peak levels, e.g. liver impairment.<br />If signs of cardiac arrhythmia occur during treatment with citalopram, the treatment should be withdrawn and an ECG should be performed.</p><p>Excipients<br />The caplets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not receive this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacodynamic interactions<br />At the pharmacodynamic level cases of serotonin syndrome with citalopram and moclobemide and buspirone have been reported.</p><p>Contraindicated combinations<br /><em>MAO-inhibitors</em></p><p>The simultaneous use of citalopram and MAO-inhibitors can result in severe undesirable effects, including serotonin syndrome (see section 4.3).<br />Cases of serious and sometimes fatal reactions have been reported in patients receiving an SSRI in combination with a monoamine oxidase inhibitor (MAOI), including the irreversible MAOI selegiline and the reversible MAOIs linezolid and moclobemide and in patients who have recently discontinued an SSRI and have been started on a MAOI.<br />Some cases presented with features resembling serotonin syndrome. Symptoms of an active substance interaction with a MAOI include: agitation, tremor, myoclonus, and hyperthermia.</p><p><em>QT interval prolongation</em><br />Pharmacokinetic and pharmacodynamic studies between citalopram and other medicinal products that prolong the QT interval have not been performed. An additive effect of citalopram and these medicinal products cannot be excluded. Therefore, co-administration of citalopram with medicinal products that prolong the QT interval, such as Class IA and III antiarrhythmics, antipsychotics (e.g. phenothiazine derivatives, pimozide, haloperidol), tricyclic antidepressants, certain antimicrobial agents (e.g. sparfloxacin, moxifloxacin, erythromycin IV, pentamidine, anti-malarial treatment particularly halofantrine), certain antihistamines (astemizole, mizolastine) etc., is contraindicated.</p><p>Pimozide<br />Co-administration of a single dose of pimozide 2 mg to subjects treated with racemic citalopram 40 mg/day for 11 days caused an increase in AUC and Cmax of pimozide, although not consistently throughout the study. The co-administration of pimozide and citalopram resulted in a mean increase in the QTc interval of approximately 10 msec. Due to the interaction noted at a low dose of pimozide, concomitant administration of citalopram and pimozide is contraindicated.</p><p><em>Combinations requiring precaution for use<br />Selegiline (selective MAO-B inhibitor)</em><br />A pharmacokinetic / pharmacodynamic interaction study with concomitantly administered citalopram (20 mg daily) and selegiline (10 mg daily) (a selective MAO B inhibitor) demonstrated no clinically relevant interactions. The concomitant use of citalopram and selegiline (in doses above 10 mg daily) is contraindicated.</p><p><em>Serotonergic medicinal products</em><br />Lithium and tryptophan<br />No pharmacodynamic interactions have been found in clinical studies in which citalopram has been given concomitantly with lithium. However there have been reports of enhanced effects when SSRIs&nbsp;have been given with lithium or tryptophan and therefore the concomitant use of citalopram with these medicinal products should be undertaken with caution. Routine monitoring of lithium levels should be continued as usual.<br />Co-administration with serotonergic medicinal products (e.g. tramadol, sumatriptan) may lead to enhancement of 5-HT associated effects.<br />Until further information is available, the simultaneous use of citalopram and 5-HT agonists, such as sumatriptan and other triptans, is not recommended (see section 4.4).</p><p><em>St. John&#39;s wort</em><br />Dynamic interactions between SSRIs and the herbal remedy St John&#39;s wort (Hypericum perforatum) can occur, resulting in an increase in undesirable effects (see section 4.4). Pharmacokinetic interactions have not been investigated.</p><p><em>Haemorrhage</em><br />Caution is warranted for patients who are being treated simultaneously with anticoagulants, medicinal products that affect the platelet function, such as non steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid, dipyridamole, and ticlopidine or other medicines (e.g. atypical antipsychotics) that can increase the risk of haemorrhage (see section 4.4).</p><p><em>ECT (electroconvusive therapy)</em><br />There are no clinical studies establishing the risks or benefits of the combined use of electroconvulsive therapy (ECT) and citalopram (see section 4.4).</p><p><em>Alcohol</em><br />No pharmacodynamic or pharmacokinetic interactions have been demonstrated between citalopram and alcohol. However, the combination of citalopram and alcohol is not advisable.</p><p><em>Medicinal products inducing hypokalaemia/hypomagnesaemia</em><br />Caution is warranted for concomitant use of hypokalaemia- / hypomagnesaemia-inducing medicinal products as these conditions increase the risk of malignant arrhythmias.</p><p><em>Medicinal products lowering the seizure threshold</em><br />SSRIs can lower the seizure threshold. Caution is advised when concomitantly using other medicinal products capable of lowering the seizure threshold (e.g. antidepressants [SSRIs], neuroleptics [thioxanthenes and butyrophenones]), mefloquine, bupropion and tramadol).</p><p>Pharmacokinetic interactions<br />Biotransformation of citalopram to demethylcitalopram is mediated by CYP2C19 (approx. 38%), CYP3A4 (approx. 31%) and CYP2D6 (approx. 31%) isozymes of the cytochrome P450 system. The fact that citalopram is metabolised by more than one CYP means that inhibition of its biotransformation is less likely as inhibition of one enzyme may be compensated by another. Therefore co-administration of citalopram with other medicinal products in clinical practice has very low likelihood of producing pharmacokinetic medicinal product interactions.</p><p><em>Food</em><br />The absorption and other pharmacokinetic properties of citalopram have not been reported to be affected by food.</p><p>Effect of other medicinal products on the pharmacokinetics of citalopram<br />Co-administration with ketoconazole (potent CYP3A4 inhibitor) did not change the pharmacokinetics of citalopram.<br />A pharmacokinetic interaction study of lithium and citalopram did not reveal any pharmacokinetic interactions (see also above).</p><p>Cimetidine<br />Cimetidine (potent CYP2D6, 3A4 and 1A2 inhibitor) caused a moderate increase in the average steady state levels of citalopram. Caution is advised when administering citalopram in combination with cimetidine. Dose adjustment may be warranted.<br />Co-administration of escitalopram (the active enantiomer of citalopram) with omeprazole 30 mg once daily (a CYP2C19 inhibitor) resulted in moderate (approximately 50%) increase in the plasma concentrations of escitalopram. Thus, caution should be exercised when used concomitantly with CYP2C19 inhibitors (e.g. omeprazole, esomeprazole, fluvoxamine, lansoprazole, ticlopidine). A reduction in the dose of citalopram may be necessary based on monitoring of undesirable effects during concomitant treatment.</p><p>Metoprolol<br />Escitalopram (the active enantiomer of citalopram) is an inhibitor of the enzyme CYP2D6. Caution is recommended when citalopram is co-administered with medicinal products that are mainly metabolised by this enzyme, and that have a narrow therapeutic index, e.g. flecainide, propafenone and metoprolol (when used in cardiac failure), or some CNS acting medicinal products that are mainly metabolised by CYP2D6, e.g. antidepressants such as desipramine, clomipramine and nortriptyline or antipsychotics like risperidone, thioridazine and haloperidol. Dosage adjustment may be warranted. Co-administration with metoprolol resulted in a twofold increase in the plasma levels of metoprolol, but did not statistically significant increase the effect of metoprolol on the blood pressure and cardiac rhythm.</p><p>Effects of citalopram on other medicinal products<br />A pharmacokinetic / pharmacodynamic interaction study with concomitant administration of citalopram and metoprolol (a CYP2D6 substrate) showed a twofold increase in metoprolol concentrations, but no statistically significant increase in the effect of metoprolol on blood pressure and heart rate in healthy volunteers.<br />Citalopram and demethylcitalopram are negligible inhibitors of CYP2C9, CYP2E1 and CYP3A4, and only weak inhibitors of CYP1A2, CYP2C19 and CYP2D6 as compared to other SSRIs established as significant inhibitors.</p><p><em>Levomepromazine, digoxin, carbamazepine</em><br />No change or only very small changes of clinical importance were observed when citalopram was given with CYP1A2 substrates (clozapine and theophylline), CYP2C9 (warfarin), CYP2C19 (imipramine and mephenytoin), CYP2D6 (sparteine, imipramine, amitriptyline, risperidone) and CYP3A4 (warfarin, carbamazepine (and its metabolite carbamazepine epoxid) and triazolam).<br />No pharmacokinetic interaction was observed between citalopram and levomepromazine, or digoxin, (indicating that citalopram neither induces nor inhibits P-glycoprotein).</p><p><em>Desipramine, imipramine</em><br />In a pharmacokinetic study no effect was demonstrated on either citalopram or imipramine levels, although the level of desipramine, the primary metabolite of imipramine was increased. When desipramine is combined with citalopram, an increase of the desipramine plasma concentration has been observed. A reduction of the desipramine dose may be needed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Pregnancy category: C<br />Published data on pregnant women (more than 2500 exposed outcomes) indicate no malformative foeto / neonatal toxicity, however, citalopram should not be used during pregnancy unless clearly necessary and only after careful consideration of risk/benefit.<br />Neonates should be observed if maternal use of citalopram continues into the later stages of pregnancy, particular in the third trimester. Abrupt discontinuation should be avoided during pregnancy.</p><p>The following symptoms may occur in the neonates after maternal SSRI/SNRI use in later stages of pregnancy: respiratory distress, cyanosis, apnoea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycaemia, hypertonia, hypotonia, hyperreflexia, tremor, jitteriness, irritability, lethargy, constant crying, somnolence and difficulty sleeping. These symptoms could be due to either serotonergic effects or discontinuation symptoms. In a majority of instances the complications begin immediately or soon (&lt;24 hours) after delivery.<br />Epidemiological data have suggested that the use of SSRIs in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). The observed risk was approximately 5 cases per 1000 pregnancies. In the general population 1 to 2 cases of PPHN per 1000 pregnancies occur.</p><p>Breast-feeding<br />Citalopram is excreted into breast milk. It is estimated that the suckling infant will receive about 5% of the weight related maternal daily dose (in mg/kg). No or only minor events have been observed in the infants. However, the existing information is insufficient for assessment of the risk to the child.<br />Caution is recommended. If treatment with citalopram is considered necessary, discontinuation of breast feeding should be considered.</p><p>Fertility<br />Animal data have shown that citalopram may affect sperm quality (see section 5.3).<br />Human case reports with some SSRIs have shown that an effect on sperm quality is reversible.<br />Impact on human fertility has not been observed so far.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Citalopram has minor or moderate influence on the ability to drive and use machines.<br />Patients who are prescribed psychotropic medication may be expected to have some impairment of general attention and concentration due to the illness itself and psychoactive medicinal products can reduce the ability to make judgements and to react to emergencies. Patients should be informed of these effects and be warned that their ability to drive a car or operate machinery could be affected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse effects observed with citalopram are in general mild and transient. They are most frequent during the first one or two weeks of treatment and usually attenuate subsequently. The adverse reactions are presented at the MedDRA Preferred Term Level.</p><p>For the following reactions a dose-response was discovered: Sweating increased, dry mouth, insomnia, somnolence, diarrhoea, nausea and fatigue.</p><p>The table shows the percentage of adverse drug reactions associated with SSRIs and/or citalopram seen in either &ge; 1% of patients in double-blind placebo-controlled trials or in the post-marketing period. Frequencies are defined as: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1000 to &lt;1/100); rare (&ge;1/10000 to &lt;1/1000); very rare (&lt;1/10000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="1" cellpadding="1" style="width:1011px"><tbody><tr><td style="width:353px"><strong>System organ class</strong></td><td style="width:163px"><strong>Frequency</strong></td><td style="width:489px"><strong>Undesirable effect</strong></td></tr><tr><td style="width:353px">Blood and lymphatic disorders</td><td style="width:163px">Not known</td><td style="width:489px">Thrombocytopenia</td></tr><tr><td style="width:353px">Immune system disorders</td><td style="width:163px">Not known</td><td style="width:489px">Hypersensitivity, anaphylactic reaction</td></tr><tr><td style="width:353px">Endocrine disorders</td><td style="width:163px">Not known</td><td style="width:489px">Inappropriate ADH secretion</td></tr><tr><td style="width:353px">Metabolism and nutrition disorders</td><td style="width:163px">Common</td><td style="width:489px">Appetite decreased, weight decreased</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Uncommon</td><td style="width:489px">Increased appetite, weight increased</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Rare</td><td style="width:489px">Hyponatraemia</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Not known</td><td style="width:489px">Hypokalaemia</td></tr><tr><td style="width:353px">Psychiatric disorders</td><td style="width:163px">Very common</td><td style="width:489px">Sleep disorder</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Common</td><td style="width:489px">Agitation, libido decreased, anxiety, nervousness, confusional state, abnormal orgasm (female), abnormal dreams, apathy</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Uncommon</td><td style="width:489px">Aggression, depersonalisation, hallucination, mania, libido increased</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Not known</td><td style="width:489px">Panic attack, bruxism, restlessness, suicidal ideation, suicidal behaviour<sup>1</sup></td></tr><tr><td style="width:353px">Nervous system disorders</td><td style="width:163px">Very common</td><td style="width:489px">Somnolence, insomnia, headache</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Common</td><td style="width:489px">Tremor, paraesthesia, dizziness, disturbance in attention, migraine, amnesia</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Uncommon</td><td style="width:489px">Syncope</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Rare</td><td style="width:489px">Convulsion grand mal, dyskinesia, taste disturbance</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Not known</td><td style="width:489px">Convulsions, serotonin syndrome, extrapyramidal disorder, akathisia, movement disorder</td></tr><tr><td style="width:353px">Eye disorders</td><td style="width:163px">Uncommon</td><td style="width:489px">Mydriasis (which may lead to acute narrow angle glaucoma), see section 4.4 Special warnings and precautions for use</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Not known</td><td style="width:489px">Visual disturbance</td></tr><tr><td style="width:353px">Ear and labyrinth disorders</td><td style="width:163px">Common</td><td style="width:489px">Tinnitus</td></tr><tr><td style="width:353px">Cardiac disorders</td><td style="width:163px">Common</td><td style="width:489px">Palpitations</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Uncommon</td><td style="width:489px">Bradycardia, tachycardia</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Not known</td><td style="width:489px">QT-prolongation, ventricular arrhythmia including torsade de pointes</td></tr><tr><td style="width:353px">Vascular disorders</td><td style="width:163px">Rare</td><td style="width:489px">Haemorrhage</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Not known</td><td style="width:489px">Orthostatic hypotension</td></tr><tr><td style="width:353px">Respiratory thoracic and mediastinal disorders</td><td style="width:163px">Common</td><td style="width:489px">Yawning, rhinitis</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Rare</td><td style="width:489px">Coughing</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Not known</td><td style="width:489px">Epistaxis</td></tr><tr><td style="width:353px">Gastrointestinal disorders</td><td style="width:163px">Very common</td><td style="width:489px">Dry mouth, nausea</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Common</td><td style="width:489px">Diarrhoea, vomiting, constipation, dyspepsia, abdominal pain, flatulence, salivary hypersecretion</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Not known</td><td style="width:489px">Gastrointestinal haemorrhage (including rectal haemorrhage)</td></tr><tr><td style="width:353px">Hepatobiliary disorders</td><td style="width:163px">Rare</td><td style="width:489px">Hepatitis</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Not known</td><td style="width:489px">Liver function test abnormal</td></tr><tr><td style="width:353px">Skin and subcutaneous tissue disorders</td><td style="width:163px">Very common</td><td style="width:489px">Sweating increased</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Common</td><td style="width:489px">Pruritus</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Uncommon</td><td style="width:489px">Urticaria, alopecia, rash, purpura, photosensitivity reaction</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Not known</td><td style="width:489px">Ecchymosis, angioedemas</td></tr><tr><td style="width:353px">Musculoskeletal and, connective tissue disorders</td><td style="width:163px">Common</td><td style="width:489px">Myalgia, arthralgia</td></tr><tr><td style="width:353px">Renal and urinary disorders</td><td style="width:163px">Uncommon</td><td style="width:489px">Urinary retention</td></tr><tr><td style="width:353px">Reproductive system and breast disorders</td><td style="width:163px">Common</td><td style="width:489px">Impotence, ejaculation disorder, ejaculation failure</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Uncommon</td><td style="width:489px">Female: Menorrhagia</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Not known</td><td style="width:489px">Female: Metrorrhagia<br />Male: Priapism<br />Galactorrhoea</td></tr><tr><td style="width:353px">General disorders and administration site conditions</td><td style="width:163px">Very common</td><td style="width:489px">Asthenia</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Common</td><td style="width:489px">Fatigue</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Uncommon</td><td style="width:489px">Oedema</td></tr><tr><td style="width:353px">&nbsp;</td><td style="width:163px">Rare</td><td style="width:489px">Pyrexia, malaise</td></tr></tbody></table><p>Number of patients: citalopram / placebo = 1346 / 545</p><p><sup>1</sup> Cases of suicidal ideation and suicidal behaviours have been reported during citalopram therapy or early after treatment discontinuation (see section 4.4).</p><p>Cases of QT-prolongation and ventricular arrhythmia including torsade de pointes have been reported during the post-marketing period, predominantly in patients of female gender, with hypokalaemia, or with pre-existing QT prolongation or other cardiac diseases (see sections 4.3, 4.4, 4.5, 4.9 and 5.1).</p><p>Class effects<br />Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving SSRIs and TCAs. The mechanism leading to this risk is unknown.</p><p>Withdrawal symptoms seen on discontinuation of SSRI treatment.<br />Discontinuation of citalopram (particularly when abrupt) commonly leads to withdrawal symptoms. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor, confusion, sweating, headache, diarrhoea, palpitations, emotional instability, irritability, and visual disturbances are the most commonly reported reactions. Generally these events are mild to moderate and are self-limiting, however, in some patients they may be severe and/or prolonged. It is therefore advised that when citalopram treatment is no longer required, gradual discontinuation by dose tapering should be carried out (see section 4.2 and section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Toxicity<br />Comprehensive clinical data on citalopram overdose are limited and many cases involve concomitant overdoses of other drugs/alcohol. Fatal cases of citalopram overdose have been reported with citalopram alone; however, the majority of fatal cases have involved overdose with concomitant medications.<br />Fatal dose is not known. Patients have survived ingestion of more than 2 g citalopram.<br />The effects may be potentiated by alcohol taken at the same time.<br />Potential interaction with TCAs, MAOIs and other SSRIs.</p><p>Symptoms</p><p>The following symptoms have been seen in reported overdose of citalopram: convulsion, tachycardia, somnolence, QT prolongation, coma, vomiting, tremor, hypotension, cardiac arrest, nausea, serotonin syndrome, agitation, bradycardia, dizziness, bundle branch block, QRS prolongation, hypertension, mydriasis, torsade de pointes, stupor, sweating, cyanosis, hyperventilation, hyperpyrexia, and atrial and ventricular arrhythmia.</p><p>ECG changes including nodal rhythm, prolonged QT intervals and wide QRS complexes may occur. Fatalities have been reported.<br />Prolonged bradycardia with severe hypotension and syncope has also been reported.</p><p>Rarely, features of the &quot;serotonin syndrome&quot; may occur in severe poisoning. This includes alteration of mental status, neuromuscular hyperactivity and autonomic instability. There may be hyperpyrexia and elevation of serum creatine kinase. Rhabdomyolysis is rare.</p><p>Treatment<br />There is no known specific antidote to citalopram.<br />Treatment should be symptomatic and supportive and include the maintenance of a clear airway and monitoring of ECG and vital signs until stable. ECG monitoring is advisable in case of overdose in patients with congestive heart failure/bradyarrhythmias, in patients using concomitant medications that prolong the QT interval, or in patients with altered metabolism, e.g. liver impairment.<br />Consider oral activated charcoal in adults and children who have ingested more than 5 mg/kg body weight within 1 hour. Activated charcoal given &frac12; hour after ingestion of citalopram has been shown to reduce absorption by 50%.<br />Osmotically working laxative (such as sodium sulphate) and stomach evacuation should be considered.<br />If consciousness is impaired the patient should be intubated.<br />Control convulsions with intravenous diazepam if they are frequent or prolonged.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antidepressants, selective serotonin reuptake inhibitors<br />ATC-code: N 06 AB 04</p><p>Mechanism of action</p><p>Biochemical and behavioural studies have shown that citalopram is a potent inhibitor of the serotonin (5-HT)-uptake. Tolerance to the inhibition of 5-HT-uptake is not induced by long-term treatment with citalopram.</p><p>Citalopram is a very Selective Serotonin Reuptake Inhibitor (SSRI), with no, or minimal, effect on noradrenaline (NA), dopamine (DA) and gamma aminobutyric acid (GABA) uptake.</p><p>In contrast to many tricyclic antidepressants and some of the newer SSRIs, citalopram has no or very low affinity for a series of receptors including 5-HT R1A, R5-HTR2R, DA DR1R and DR2R receptors, &alpha;R1R-, &alpha;R2R-, &beta;-adrenoceptors, histamine HR1R, muscarine cholinergic, benzodiazepine, and opioid receptors. A series of functional in vitro tests in isolated organs as well as functional in vivo tests have confirmed the lack of receptor affinity.</p><p>This absence of effects on receptors could explain why citalopram produces fewer of the traditional side effects such as dry mouth, bladder and gut disturbance, blurred vision, sedation, cardiotoxicity and orthostatic hypotension.<br />The main metabolites of citalopram are all SSRIs although their potency and selectivity ratios are lower than those of citalopram. However, the selectivity ratios of the metabolites are higher than those of many of the newer SSRIs. The metabolites do not contribute to the overall antidepressant effect.</p><p>Pharmacodynamic effects</p><p>Suppression of rapid eye movement (REM) sleep is considered a predictor of antidepressant activity. Like tricyclic antidepressants, other SSRIs and MAO inhibitors, citalopram suppresses REM-sleep and increases deep slow-wave sleep.<br />Although citalopram does not bind to opioid receptors it potentiates the anti-nociceptive effect of commonly used opioid analgesics. There was potentiation of d-amphetamine-induced hyperactivity following administration of citalopram.</p><p>In humans citalopram does not impair cognitive (intellectual function) and psychomotor performance and has no or minimal sedative properties, either alone or in combination with alcohol.<br />Citalopram did not reduce saliva flow in a single dose study in human volunteers and in none of the studies in healthy volunteers did citalopram have significant influence on cardiovascular parameters. Citalopram has no effect on the serum levels of prolactin and growth hormone.<br />In a double-blind, placebo-controlled ECG study in healthy subjects, the change from baseline in QTc (Fridericia-correction) was 7.5 (90%CI 5.9-9.1) msec at the 20 mg/day dose and 16.7 (90%CI 15.0-18.4) msec at the 60 mg day/dose (see sections 4.3, 4.4, 4.5, 4.8 and 4.9).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Absorption is almost complete and independent of food intake (T RmaxRaverage/mean 3.8 hours). Oral bioavailability is about 80%.</p><p>Distribution<br />The apparent volume of distribution (VRdR)R&beta; Ris about 12.3 L/kg. The plasma protein binding is below 80% for citalopram and its main metabolites.</p><p>Biotransformation<br />Citalopram is metabolized to the active demethylcitalopram, didemethylcitalopram, citalopram-N-oxide and an inactive deaminated propionic acid derivative. All the active metabolites are also SSRIs, although weaker than the parent compound. Unchanged citalopram is the predominant compound in plasma.</p><p>Elimination<br />The elimination half-life (TR&frac12;&beta;R) is about 1.5 days and the systemic citalopram plasma clearance (ClRsR) is about 0.33 L/min, and oral plasma clearance (ClR oralR) is about 0.41 L/min.<br />Citalopram is excreted mainly via the liver (85%) and the remainder (15%) via the kidneys. About 12% of the daily dose is excreted in urine as unchanged citalopram. Hepatic (residual) clearance is about 0.35 L/min and renal clearance about 0.068 L/min.<br />The kinetics are linear. Steady state plasma levels are achieved in 1-2 weeks. Average concentrations of 250 nmol/L (100-500 nmol/L) are achieved at a daily dose of 40 mg. There is no clear relationship between citalopram plasma levels and therapeutic response or side effects.</p><p>Elderly patients (&ge; 65 years)<br />Longer half-lives and decreased clearance values due to a reduced rate of metabolism have been demonstrated in elderly patients.</p><p>Reduced hepatic function<br />Citalopram is eliminated more slowly in patients with reduced hepatic function. The half-life of citalopram is about twice as long and steady state citalopram concentrations at a given dose will be about twice as high as in patients with normal liver function.</p><p>Reduced renal function<br />Citalopram is eliminated more slowly in patients with mild to moderate reduction of renal function, without any major impact on the pharmacokinetics of citalopram. At present no information is available for treatment of patients with severely reduced renal function (creatinine clearance &lt;20 mL/min).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acute toxicity<br />Citalopram has low acute toxicity.</p><p>Chronic toxicity<br />In chronic toxicity studies there were no findings of concern for the therapeutic use of citalopram.</p><p>Reproduction studies<br />Based on data from reproduction toxicity studies (segment I, II and III) there is no reason to have special concern for the use of citalopram in women of child-bearing potential.<br />Animal data have shown that citalopram induces a reduction of fertility index and pregnancy index, reduction in the implantation number and abnormal sperm at exposure well in excess of human exposure.</p><p>Mutagenic and carcinogenic potential<br />Citalopram has no mutagenic or carcinogenic potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Maize starch/ Povidone/ Croscarmellose/ Lactose monohydrate/ Microcrystalline Cellulose 101 / Microcrystalline Cellulose 102 / Colloidal silicone dioxide/ Magnesium Stearate/Luster Clear (Microcrystalline Cellulose, Carrageenan, Polyethylene Glycol) / Titanium Dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/ PVDC- Aluminum Foil Blister pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jordan Sweden Medical and Sterilization
Joswe-medical
P.O. Box 851831 Amman 11185 Jordan
E-mail: joswe@go.com.jo
www.joswe.com
Tel: +962 6 5859765, +962 6 5728327
Fax: +962 6 5814526, +962 6 5728326
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10th February 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>